Influenza
Conditions
Brief summary
The study hypothesis is that two 0.5 ml doses of non-adjuvanted whole virion monovalent A/H1N1 influenza vaccine (IVACFLU)--each dose with an HA content of 15 mcg from A/California/07/2009 (H1N1)-like virus--will be safe and immunogenic in healthy adults.
Detailed description
This is a phase I, double-blind, individually-randomized (1:1, vaccine:placebo), controlled trial with two groups, IVACFLU (A/H1N1) and placebo. Healthy male and female adults 18 through 40 years of age will be invited to participate. In addition to sponsor monitoring of safety, Program for Appropriate Technology in Health (PATH) will review safety data. Safety data through 7 days post-dose one for all subjects will be reviewed in a blinded fashion prior to administration of dose two of study vaccine or placebo. PATH will review all adverse events (AEs), including clinical laboratory evaluations (pre- and post-vaccination) and will advise if the volunteers may receive dose two of study vaccine or placebo. For all subjects, the procedures and timelines are summarized below. On the day of first screening (S1), about 14 days (between 5 and 30 days) prior to administration of dose one of study vaccine or placebo, subjects will be screened for eligibility through medical history review, physical examination, testing for serologic evidence of chronic viral infection \[human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)\], routine biochemical and hematological blood tests and urinalysis by dipstick. For screening for serologic evidence of chronic viral infections, appropriate pre- and post-test counseling must be provided. Subject screening for eligibility will continue and be completed on the second screening day (S2). This second screening day will occur the same day as scheduled enrollment into the trial and administration of study vaccine or placebo (Day 0). Women will undergo pregnancy tests using urine samples on Day 0. Fully eligible subjects will be enrolled into the trial. At that time, blood specimens will be collected for immunological testing prior to administration of study vaccine or placebo. Subjects will be unaware of which allocation, IVACFLU or placebo, is received; study vaccine and placebo will be masked. Subjects will be carefully monitored for adverse reactions for 60 minutes after vaccination. During the first week following vaccination, subjects will be asked to record local and general signs and symptoms using preprinted diary cards, thermometer, and small ruler. Concomitant medications will also be recorded. In addition to solicited signs, subjects will be asked to report any other adverse events, whether or not they believe that the event is related to the vaccination. Member of the investigator's clinical team will visit subjects one and five days after vaccination to check that subjects are correctly completing the diary card and to check on the subjects' well-being. Subjects will then return to the study clinic 7 days after dose one. At that time, the investigator will check the subjects' diary cards and transcribe all adverse events onto the case report forms using medical language. Blood and urine specimens will also be collected for routine biochemical and hematological blood tests and urinalysis by dipstick. Two days before subjects are scheduled to receive dose two, subjects will be visited or called to remind them of the next visit to the study clinic and to check on the subjects' well-being. Subjects will return to the study clinic at 3 weeks after administration of dose one of study vaccine or placebo in order to receive dose two. At that time, interim histories and concomitant medications will be reviewed. Women will again undergo urine pregnancy tests. All subjects will undergo collection of blood and urine specimens for routine biochemical and hematological blood tests and urinalysis by dipstick and collection of blood serum specimens for immunologic analyses. Then subjects will receive dose two of study vaccine or placebo and be monitored for 60 minutes. After receipt of dose two, subjects will again complete diary cards for 7 days after vaccination with visits by members of the investigator's clinical team again at days one and five after vaccination to check that the subjects are correctly completing diary cards and to check on the subjects' well-being. Subjects will then return to the study clinic 7 days after dose two (Day 28) for review of diary cards by the investigator and collection of blood and urine specimens for routine biochemical and hematological blood tests and urinalysis by dipstick. Two days before the subjects' next scheduled visit at 3 weeks after administration of dose two, subjects will be visited or called to remind them of the next visit to the study clinic and to check on the subjects' well-being. Subjects will then return to the study clinic at 3 weeks after administration of dose two (Day 42) of study vaccine or placebo for another study visit. At that time, interim histories and concomitant medications will again be reviewed and final blood specimens will be collected for immunogenicity analyses. Women will also undergo a final pregnancy screen. Subjects will then be asked to immediately report severe adverse events (SAEs) which occur from Day 42 to Day 201 (approximately 6 months after receipt of dose two). To facilitate this reporting, a member of the investigator's team will visit or call the subjects monthly to check on their well-being. At last study visit on Day 201, subjects will be interviewed and examined one last time before completing the study. For the evaluation of serum antibodies (by hemagglutination inhibition and microneutralization), serum specimens will be collected on Day 0 (prior to administration of dose one of study vaccine or placebo), on Day 21 (prior to administration of dose two of study vaccine or placebo) and on Day 42.
Interventions
BIOLOGICALIVACFLU
IVACFLU is a whole virus vaccine, collected in a linear sucrose density gradient solution using a continuous flow centrifuge Alfpa Wassmann and inactivated with formaldehyde. It was formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009(H1N1)-like virus per 0.5 mL dose and filled in single dose vials.
OTHERPlacebo
Phosphate buffered saline (PBS), pH 7.2, in 0.5 ml single-dose vials.
Sponsors
Institute of Vaccines and Medical Biologicals, Vietnam
Pasteur Institute, Ho Chi Minh City
PATH
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female adult 18 (age of legal consent in Vietnam) through 40 years of age at the enrollment visit. * Literate and willing to provide written informed consent. * Free of obvious health problems, as established by the medical history and screening evaluations, including physical examination. * Capable and willing to complete diary cards and willing to return for all follow-up visits * For females, willing to utilize reliable birth control measures (intrauterine device, birth control pills, condoms) through the Day 42 visit.
Exclusion criteria
* Participation in another clinical trial involving any therapy within the previous three months or planned enrollment in such a trial during the period of this study. * Receipt of any non-study vaccine within four weeks prior to enrollment or refusal to postpone receipt of such vaccines until after the Day 42 visit. * Current or recent (within two weeks of enrollment) acute illness with or without fever. * Receipt of immune globulin or other blood products within three months prior to study enrollment or planned receipt of such products prior to the Day 42 visit. * Chronic administration (defined as more than 14 consecutively-prescribed days) of immunosuppressants or other immune-modulating therapy within six months prior to study enrollment. (For corticosteroids, this means prednisone or equivalent, \>=0.5 mg per kg per day; topical steroids are allowed.) * History of asthma. * Hypersensitivity after previous administration of any vaccine. * Other AE following immunization, at least possibly related to previous receipt of any vaccine. * Suspected or known hypersensitivity to any of the study vaccine components, including chicken or egg protein. * Known hypersensitivities (allergies) to food or the natural environment. * Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, metabolic, neurologic, psychiatric or renal functional abnormality, as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives.. * History of leukemia or any other blood or solid organ cancer. * History of thrombocytopenic purpura or known bleeding disorder. * History of seizures. * Known or suspected immunosuppressed or immunodeficient condition of any kind, including HIV infection. * Known chronic HBV or HCV infection. * Known active tuberculosis or symptoms of active tuberculosis, regardless of cause. * History of chronic alcohol abuse and/or illegal drug use. * Pregnancy or lactation. (A negative pregnancy test will be required before administration of study vaccine or placebo for all women of childbearing potential.) * History of Guillain-Barre' Syndrome * Any condition that, in the opinion of the investigator, would increase the health risk to the subject if he/she participates in the study or would interfere with the evaluation of the study objectives.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Maximum Systemic Reaction After Vaccination 1 | 7 days | Systemic and local reactogenicity data were collected on Study Days 0, 7, 21 and 28, prevaccination, and within 60 minutes post-vaccination by clinic staff. Subjects completed diary cards for 7 days after each vaccination and received visits from the investigator's clinical team at Days 1 and 5 following each vaccination. Solicited systemic reactogenicity events included body temperature, feverishness, chills, cough, difficulty breathing, runny nose, nasal congestion, sore throat, hoarseness of voice, headache, confusion, convulsions/seizures, fatigue/malaise, muscle aches, joint pain, pink or red eyes, sore eyes, itchy eyes, drainage from eyes, ear pain or discharge, rash, abdominal pain, diarrhea, vomiting and jaundice. Solicited local reactogenicity included size of redness, size of swelling, size of induration, pain, and tenderness. |
| Number of Participants With Maximum Systemic Reaction After Vaccination 2 | 7 days | Systemic and local reactogenicity data were collected on Study Days 0, 7, 21 and 28, prevaccination, and within 60 minutes post-vaccination by clinic staff. Subjects completed diary cards for 7 days after each vaccination and received visits from the investigator's clinical team at Days 1 and 5 following each vaccination. Solicited systemic reactogenicity events included body temperature, feverishness, chills, cough, difficulty breathing, runny nose, nasal congestion, sore throat, hoarseness of voice, headache, confusion, convulsions/seizures, fatigue/malaise, muscle aches, joint pain, pink or red eyes, sore eyes, itchy eyes, drainage from eyes, ear pain or discharge, rash, abdominal pain, diarrhea, vomiting and jaundice. Solicited local reactogenicity included size of redness, size of swelling, size of induration, pain, and tenderness. |
| Number of Participants With Maximum Local Reaction After Vaccination 1 | 7 days | Systemic and local reactogenicity data were collected on Study Days 0, 7, 21 and 28, prevaccination, and within 60 minutes post-vaccination by clinic staff. Subjects completed diary cards for 7 days after each vaccination and received visits from the investigator's clinical team at Days 1 and 5 following each vaccination. Solicited local reactogenicity included size of redness, size of swelling, size of induration, pain, and tenderness. |
| Number of Participants With Maximum Local Reaction After Vaccination 2 | 7 days | Systemic and local reactogenicity data were collected on Study Days 0, 7, 21 and 28, prevaccination, and within 60 minutes post-vaccination by clinic staff. Subjects completed diary cards for 7 days after each vaccination and received visits from the investigator's clinical team at Days 1 and 5 following each vaccination. Solicited local reactogenicity included size of redness, size of swelling, size of induration, pain, and tenderness. |
| Unsolicited, Non-serious Adverse Events | 7 days after each dose (Day 7 and Day 28) | Subjects completed diary cards for 7 days after each vaccination and received visits from the investigator's clinical team at Days 1 and 5 following each vaccination. Adverse events were collected throughout the study period, and were graded for severity; however unsolicited adverse events were assessed only for relationship to vaccine if the events were immediate reactions or considered to be serious adverse events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number and Percentage of Subjects Developing a Seroprotective Hemagglutination-inhibition (HAI) Antibody Titer | Day 21 and Day 42 | Seroprotection defined as an HAI titer ≥1:40. Day 21 and 42 blood samples from study subjects (n=48) were tested. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The hemagglutination titer was reported as the reciprocal of the highest dilution that caused hemagglutination and was expressed in HA units (HAU)/50μL, calculated as the average of results of duplicate wells. |
| Geometric Mean Titer of Microneutralizing (MN) Antibodies | Day 0, Day 21 and Day 42 | Day 0, 21 and 42 specimens were tested in the microneutralization (MN) assay. The microneutralization assay determines the titer of neutralizing antibodies against influenza A/H1N1. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The 50% neutralizing antibody titer is the reciprocal of the corresponding serum dilution. The geometric mean titers (GMT) and corresponding confidence intervals were based on a log 10 scale. |
| Ratio of Geometric Mean Titer of Microneutralization (MN) Antibodies | Day 0, Day 21 and Day 42 | Day 0, 21 and 42 specimens were tested in the microneutralization (MN) assay. The microneutralization assay determines the titer of neutralizing antibodies against influenza A/H1N1. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The 50% neutralizing antibody titer is the reciprocal of the corresponding serum dilution. The geometric mean titers (GMT) and corresponding confidence intervals were based on a log 10 scale. |
| Geometric Mean Titer of Hemagglutination-inhibition Antibodies (HAI) | Day 0, Day 21 and Day 42 | Day 0, 21 and 42 blood samples from study subjects (n=48) were tested. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The hemagglutination titer was reported as the reciprocal of the highest dilution that caused hemagglutination and was expressed in HA units (HAU)/50μL, calculated as the average of results of duplicate wells. |
| Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Less Than 40 | Day 21 and Day 42 | Day 21 and 42 blood samples from study subjects (n=48) were tested. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The hemagglutination titer was reported as the reciprocal of the highest dilution that caused hemagglutination and was expressed in HA units (HAU)/50μL, calculated as the average of results of duplicate wells. |
| Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Greater Than 40 | Day 21 and Day 42 | Day 21 and 42 specimens were tested in the microneutralization (MN) assay. The microneutralization assay determines the titer of neutralizing antibodies against influenza A/H1N1. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The 50% neutralizing antibody titer is the reciprocal of the corresponding serum dilution. The geometric mean titers (GMT) and corresponding confidence intervals were based on a log 10 scale. |
| Number and Percentage of Subjects Developing a Seroprotective Microneutralizing (MN) Antibody Titer | Day 21 and Day 42 | Seroprotection defined as an antibody titer of 1:40 or greater. Day 21 and 42 specimens were tested in the microneutralization (MN) assay. The microneutralization assay determines the titer of neutralizing antibodies against influenza A/H1N1. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The 50% neutralizing antibody titer is the reciprocal of the corresponding serum dilution. The geometric mean titers (GMT) and corresponding confidence intervals were based on a log 10 scale. |
| Number and Percentage of All Subjects Achieving a Four-fold Rise in Microneutralization (MN) Antibodies | Day 21 and Day 42 | Day 21 and 42 specimens were tested in the microneutralization (MN) assay. The microneutralization assay determines the titer of neutralizing antibodies against influenza A/H1N1. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The 50% neutralizing antibody titer is the reciprocal of the corresponding serum dilution. The geometric mean titers (GMT) and corresponding confidence intervals were based on a log 10 scale. |
| Ratio of Geometric Mean Titer of Hemagglutination-inhibition Antibodies (HAI) | Day 0, Day 21 and Day 42 | Day 0, 21 and 42 blood samples from study subjects (n=48) were tested. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The hemagglutination titer was reported as the reciprocal of the highest dilution that caused hemagglutination and was expressed in HA units (HAU)/50μL, calculated as the average of results of duplicate wells. |
| Number and Percentage of All Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) | Day 21 and Day 42 | Day 21 and 42 blood samples from study subjects (n=48) were tested. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The hemagglutination titer was reported as the reciprocal of the highest dilution that caused hemagglutination and was expressed in HA units (HAU)/50μL, calculated as the average of results of duplicate wells. |
| Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Less Than 40 | Day 21 and Day 42 | Day 21 and Day 42 blood samples from study subjects (n=48) were tested. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The hemagglutination titer was reported as the reciprocal of the highest dilution that caused hemagglutination and was expressed in HA units (HAU)/50μL, calculated as the average of results of duplicate wells. |
| Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Greater Than 40 | Day 21 and Day 42 | Day 21 and 42 blood samples from study subjects (n=48) were tested. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The hemagglutination titer was reported as the reciprocal of the highest dilution that caused hemagglutination and was expressed in HA units (HAU)/50μL, calculated as the average of results of duplicate wells. |
Countries
Vietnam
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Influenza Vaccine Received 0.50 mL of inactivated monovalent influenza vaccine (IVACFLU), administered intramuscularly, on days 0 and 21
IVACFLU: IVACFLU is a whole virus vaccine, collected in a linear sucrose density gradient solution using a continuous flow centrifuge Alfpa Wassmann and inactivated with formaldehyde. It was formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009(H1N1)-like virus per 0.5 mL dose and filled in single dose vials. | 23 |
| Placebo Received placebo, administered intramuscularly, on days 0 and 21
Placebo: Phosphate buffered saline (PBS), pH 7.2, in 0.5 ml single-dose vials. | 25 |
| Total | 48 |
Baseline characteristics
| Characteristic | Total | Influenza Vaccine | Placebo |
|---|---|---|---|
| Age, Continuous | 29.9 years STANDARD_DEVIATION 5.85 | 28.3 years STANDARD_DEVIATION 6.31 | 31.3 years STANDARD_DEVIATION 5.11 |
| Handedness Left-handed | 7 Participants | 5 Participants | 2 Participants |
| Handedness Right-handed | 41 Participants | 18 Participants | 23 Participants |
| Height | 158.7 centimeters STANDARD_DEVIATION 6.16 | 160.5 centimeters STANDARD_DEVIATION 6.01 | 156.9 centimeters STANDARD_DEVIATION 5.9 |
| Race/Ethnicity, Customized Kinh | 48 Participants | 23 Participants | 25 Participants |
| Region of Enrollment Vietnam | 48 participants | 23 participants | 25 participants |
| Sex: Female, Male Female | 31 Participants | 13 Participants | 18 Participants |
| Sex: Female, Male Male | 17 Participants | 10 Participants | 7 Participants |
| Weight | 55.4 kilograms STANDARD_DEVIATION 7.67 | 55.7 kilograms STANDARD_DEVIATION 7.76 | 55.1 kilograms STANDARD_DEVIATION 7.74 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 23 | 0 / 25 |
| other Total, other adverse events | 11 / 23 | 15 / 25 |
| serious Total, serious adverse events | 0 / 23 | 1 / 25 |
Outcome results
Primary
Number of Participants With Maximum Local Reaction After Vaccination 1
Systemic and local reactogenicity data were collected on Study Days 0, 7, 21 and 28, prevaccination, and within 60 minutes post-vaccination by clinic staff. Subjects completed diary cards for 7 days after each vaccination and received visits from the investigator's clinical team at Days 1 and 5 following each vaccination. Solicited local reactogenicity included size of redness, size of swelling, size of induration, pain, and tenderness.
Time frame: 7 days
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 1 | Swollen after injection | Mild | 1 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 1 | Any local symptoms | None | 20 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 1 | Any local symptoms | Mild | 5 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 1 | Swollen after injection | None | 24 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 1 | Red after injection | None | 24 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 1 | Red after injection | Mild | 1 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 1 | Hardness after injection | None | 24 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 1 | Hardness after injection | Mild | 1 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 1 | Painful feeling after injection | None | 25 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 1 | Painful feeling after injection | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 1 | Pain when touching to the injection | None | 20 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 1 | Pain when touching to the injection | Mild | 5 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 1 | Pain when touching to the injection | None | 21 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 1 | Swollen after injection | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 1 | Hardness after injection | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 1 | Any local symptoms | None | 19 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 1 | Painful feeling after injection | Mild | 3 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 1 | Any local symptoms | Mild | 4 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 1 | Hardness after injection | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 1 | Swollen after injection | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 1 | Pain when touching to the injection | Mild | 2 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 1 | Red after injection | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 1 | Painful feeling after injection | None | 20 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 1 | Red after injection | Mild | 0 Participants |
Primary
Number of Participants With Maximum Local Reaction After Vaccination 2
Systemic and local reactogenicity data were collected on Study Days 0, 7, 21 and 28, prevaccination, and within 60 minutes post-vaccination by clinic staff. Subjects completed diary cards for 7 days after each vaccination and received visits from the investigator's clinical team at Days 1 and 5 following each vaccination. Solicited local reactogenicity included size of redness, size of swelling, size of induration, pain, and tenderness.
Time frame: 7 days
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 2 | Red after injection | Mild | 1 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 2 | Hardness after injection | None | 25 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 2 | Swollen after injection | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 2 | Hardness after injection | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 2 | Any local symptoms | Mild | 4 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 2 | Painful feeling after injection | None | 25 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 2 | Painful feeling after injection | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 2 | Red after injection | None | 24 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 2 | Pain when touching to the injection | None | 22 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 2 | Swollen after injection | None | 25 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 2 | Pain when touching to the injection | Mild | 3 Participants |
| Placebo | Number of Participants With Maximum Local Reaction After Vaccination 2 | Any local symptoms | None | 21 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 2 | Pain when touching to the injection | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 2 | Any local symptoms | None | 21 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 2 | Any local symptoms | Mild | 2 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 2 | Painful feeling after injection | None | 22 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 2 | Swollen after injection | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 2 | Swollen after injection | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 2 | Red after injection | None | 22 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 2 | Red after injection | Mild | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 2 | Hardness after injection | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 2 | Hardness after injection | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 2 | Painful feeling after injection | Mild | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Local Reaction After Vaccination 2 | Pain when touching to the injection | None | 23 Participants |
Primary
Number of Participants With Maximum Systemic Reaction After Vaccination 1
Systemic and local reactogenicity data were collected on Study Days 0, 7, 21 and 28, prevaccination, and within 60 minutes post-vaccination by clinic staff. Subjects completed diary cards for 7 days after each vaccination and received visits from the investigator's clinical team at Days 1 and 5 following each vaccination. Solicited systemic reactogenicity events included body temperature, feverishness, chills, cough, difficulty breathing, runny nose, nasal congestion, sore throat, hoarseness of voice, headache, confusion, convulsions/seizures, fatigue/malaise, muscle aches, joint pain, pink or red eyes, sore eyes, itchy eyes, drainage from eyes, ear pain or discharge, rash, abdominal pain, diarrhea, vomiting and jaundice. Solicited local reactogenicity included size of redness, size of swelling, size of induration, pain, and tenderness.
Time frame: 7 days
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Chills | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Fatigue/malaise | Mild | 2 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Nasal congestion | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Fatigue/malaise | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Any systemic symptoms | Mild | 9 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Muscle aches (generalized) | None | 24 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Nasal congestion | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Muscle aches (generalized) | Mild | 1 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Cough | None | 24 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Muscle aches (generalized) | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Nasal congestion | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Joint pain | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Feverishness/subjective fever | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Joint pain | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Sore throat | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Joint pain | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Cough | Mild | 1 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Pink or red eyes | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Sore throat | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Pink or red eyes | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Any systemic symptoms | None | 16 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Pink or red eyes | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Sore throat | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Sore eyes | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Cough | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Sore eyes | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Hoarseness of voice | None | 24 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Sore eyes | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Feverishness/subjective fever | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Itchy eyes | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Hoarseness of voice | Mild | 1 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Itchy eyes | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Difficulty breathing | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Itchy eyes | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Hoarseness of voice | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Drainage from eyes | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Any systemic symptoms | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Drainage from eyes | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Headache | None | 22 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Drainage from eyes | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Difficulty breathing | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Ear pain or discharge | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Headache | Mild | 3 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Ear pain or discharge | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Chills | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Rash | None | 24 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Headache | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Rash | Mild | 1 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Difficulty breathing | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Rash | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Confusion | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Abdominal pain | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Ear pain or discharge | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Abdominal pain | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Confusion | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Abdominal pain | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Runny nose | None | 23 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Diarrhea | None | 24 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Confusion | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Diarrhea | Mild | 1 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Chills | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Diarrhea | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Seizure | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Vomiting | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Runny nose | Mild | 2 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Vomiting | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Seizure | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Vomiting | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Feverishness/subjective fever | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Jaundice | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Seizure | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Jaundice | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Runny nose | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Jaundice | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Fatigue/malaise | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Jaundice | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Any systemic symptoms | None | 15 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Any systemic symptoms | Mild | 6 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Any systemic symptoms | Moderate | 2 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Feverishness/subjective fever | None | 22 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Feverishness/subjective fever | Mild | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Feverishness/subjective fever | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Chills | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Chills | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Chills | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Cough | None | 22 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Cough | Mild | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Cough | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Difficulty breathing | None | 22 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Difficulty breathing | Mild | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Difficulty breathing | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Runny nose | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Runny nose | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Runny nose | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Nasal congestion | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Nasal congestion | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Nasal congestion | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Sore throat | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Sore throat | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Sore throat | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Hoarseness of voice | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Hoarseness of voice | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Hoarseness of voice | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Headache | None | 19 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Headache | Mild | 2 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Headache | Moderate | 2 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Confusion | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Confusion | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Confusion | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Seizure | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Seizure | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Seizure | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Fatigue/malaise | None | 20 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Fatigue/malaise | Mild | 3 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Fatigue/malaise | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Muscle aches (generalized) | None | 21 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Muscle aches (generalized) | Mild | 2 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Muscle aches (generalized) | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Joint pain | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Joint pain | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Joint pain | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Pink or red eyes | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Pink or red eyes | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Pink or red eyes | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Sore eyes | None | 22 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Sore eyes | Mild | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Sore eyes | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Itchy eyes | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Itchy eyes | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Itchy eyes | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Drainage from eyes | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Drainage from eyes | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Ear pain or discharge | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Ear pain or discharge | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Ear pain or discharge | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Rash | None | 22 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Rash | Mild | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Rash | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Abdominal pain | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Abdominal pain | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Abdominal pain | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Diarrhea | None | 22 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Diarrhea | Mild | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Diarrhea | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Vomiting | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Vomiting | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Vomiting | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Jaundice | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Jaundice | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 1 | Drainage from eyes | Moderate | 0 Participants |
Primary
Number of Participants With Maximum Systemic Reaction After Vaccination 2
Systemic and local reactogenicity data were collected on Study Days 0, 7, 21 and 28, prevaccination, and within 60 minutes post-vaccination by clinic staff. Subjects completed diary cards for 7 days after each vaccination and received visits from the investigator's clinical team at Days 1 and 5 following each vaccination. Solicited systemic reactogenicity events included body temperature, feverishness, chills, cough, difficulty breathing, runny nose, nasal congestion, sore throat, hoarseness of voice, headache, confusion, convulsions/seizures, fatigue/malaise, muscle aches, joint pain, pink or red eyes, sore eyes, itchy eyes, drainage from eyes, ear pain or discharge, rash, abdominal pain, diarrhea, vomiting and jaundice. Solicited local reactogenicity included size of redness, size of swelling, size of induration, pain, and tenderness.
Time frame: 7 days
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Chills | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Chills | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Sore throat | None | 23 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Cough | None | 24 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Joint pain | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Cough | Mild | 1 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Confusion | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Cough | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Runny nose | Mild | 5 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Pink or red eyes | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Hoarseness of voice | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Nasal congestion | None | 23 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Abdominal pain | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Pink or red eyes | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Sore eyes | None | 24 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Difficulty breathing | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Confusion | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Difficulty breathing | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Sore eyes | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Runny nose | None | 20 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Itchy eyes | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Seizure | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Itchy eyes | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Drainage from eyes | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Fatigue/malaise | None | 23 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Fatigue/malaise | Mild | 2 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Drainage from eyes | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Joint pain | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Pink or red eyes | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Seizure | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Ear pain or discharge | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Sore eyes | Mild | 1 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Seizure | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Difficulty breathing | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Itchy eyes | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Rash | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Hoarseness of voice | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Drainage from eyes | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Abdominal pain | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Diarrhea | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Ear pain or discharge | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Ear pain or discharge | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Diarrhea | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Rash | None | 22 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Runny nose | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Nasal congestion | Mild | 1 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Fatigue/malaise | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Nasal congestion | Moderate | 1 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Sore throat | Moderate | 1 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Sore throat | Mild | 1 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Hoarseness of voice | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Any systemic symptoms | None | 13 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Muscle aches (generalized) | None | 24 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Confusion | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Any systemic symptoms | Mild | 10 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Headache | None | 20 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Any systemic symptoms | Moderate | 2 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Muscle aches (generalized) | Mild | 1 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Diarrhea | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Feverishness/subjective fever | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Vomiting | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Headache | Mild | 3 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Vomiting | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Feverishness/subjective fever | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Vomiting | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Muscle aches (generalized) | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Jaundice | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Feverishness/subjective fever | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Jaundice | Mild | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Headache | Moderate | 2 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Jaundice | Moderate | 0 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Rash | Mild | 3 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Chills | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Abdominal pain | None | 25 Participants |
| Placebo | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Joint pain | None | 25 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Abdominal pain | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Sore throat | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Sore throat | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Sore throat | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Hoarseness of voice | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Hoarseness of voice | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Hoarseness of voice | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Headache | Moderate | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Confusion | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Seizure | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Fatigue/malaise | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Fatigue/malaise | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Fatigue/malaise | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Muscle aches (generalized) | None | 22 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Muscle aches (generalized) | Mild | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Muscle aches (generalized) | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Joint pain | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Joint pain | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Pink or red eyes | Mild | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Sore eyes | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Itchy eyes | Mild | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Drainage from eyes | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Ear pain or discharge | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Rash | None | 22 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Rash | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Diarrhea | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Jaundice | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Runny nose | None | 21 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Any systemic symptoms | None | 19 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Any systemic symptoms | Mild | 3 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Any systemic symptoms | Moderate | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Feverishness/subjective fever | None | 21 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Feverishness/subjective fever | Mild | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Feverishness/subjective fever | Moderate | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Chills | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Chills | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Cough | None | 20 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Cough | Mild | 3 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Runny nose | Mild | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Runny nose | Moderate | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Cough | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Difficulty breathing | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Difficulty breathing | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Difficulty breathing | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Confusion | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Seizure | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Drainage from eyes | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Seizure | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Joint pain | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Pink or red eyes | None | 22 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Pink or red eyes | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Sore eyes | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Sore eyes | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Itchy eyes | None | 22 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Itchy eyes | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Drainage from eyes | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Ear pain or discharge | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Ear pain or discharge | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Nasal congestion | None | 22 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Nasal congestion | Mild | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Nasal congestion | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Headache | None | 21 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Headache | Mild | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Confusion | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Abdominal pain | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Abdominal pain | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Diarrhea | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Diarrhea | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Vomiting | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Vomiting | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Vomiting | Moderate | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Jaundice | None | 23 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Jaundice | Mild | 0 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Rash | Mild | 1 Participants |
| Influenza Vaccine | Number of Participants With Maximum Systemic Reaction After Vaccination 2 | Chills | Mild | 0 Participants |
Primary
Unsolicited, Non-serious Adverse Events
Subjects completed diary cards for 7 days after each vaccination and received visits from the investigator's clinical team at Days 1 and 5 following each vaccination. Adverse events were collected throughout the study period, and were graded for severity; however unsolicited adverse events were assessed only for relationship to vaccine if the events were immediate reactions or considered to be serious adverse events.
Time frame: 7 days after each dose (Day 7 and Day 28)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Unsolicited, Non-serious Adverse Events | Mild | 5 adverse events |
| Placebo | Unsolicited, Non-serious Adverse Events | Moderate | 12 adverse events |
| Influenza Vaccine | Unsolicited, Non-serious Adverse Events | Mild | 14 adverse events |
| Influenza Vaccine | Unsolicited, Non-serious Adverse Events | Moderate | 11 adverse events |
Secondary
Geometric Mean Titer of Hemagglutination-inhibition Antibodies (HAI)
Day 0, 21 and 42 blood samples from study subjects (n=48) were tested. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The hemagglutination titer was reported as the reciprocal of the highest dilution that caused hemagglutination and was expressed in HA units (HAU)/50μL, calculated as the average of results of duplicate wells.
Time frame: Day 0, Day 21 and Day 42
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Placebo | Geometric Mean Titer of Hemagglutination-inhibition Antibodies (HAI) | Day 0 | 13.5 titer |
| Placebo | Geometric Mean Titer of Hemagglutination-inhibition Antibodies (HAI) | Day 21 | 306.6 titer |
| Placebo | Geometric Mean Titer of Hemagglutination-inhibition Antibodies (HAI) | Day 42 | 283.7 titer |
| Influenza Vaccine | Geometric Mean Titer of Hemagglutination-inhibition Antibodies (HAI) | Day 0 | 11.5 titer |
| Influenza Vaccine | Geometric Mean Titer of Hemagglutination-inhibition Antibodies (HAI) | Day 21 | 11.2 titer |
| Influenza Vaccine | Geometric Mean Titer of Hemagglutination-inhibition Antibodies (HAI) | Day 42 | 11.8 titer |
Secondary
Geometric Mean Titer of Microneutralizing (MN) Antibodies
Day 0, 21 and 42 specimens were tested in the microneutralization (MN) assay. The microneutralization assay determines the titer of neutralizing antibodies against influenza A/H1N1. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The 50% neutralizing antibody titer is the reciprocal of the corresponding serum dilution. The geometric mean titers (GMT) and corresponding confidence intervals were based on a log 10 scale.
Time frame: Day 0, Day 21 and Day 42
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Placebo | Geometric Mean Titer of Microneutralizing (MN) Antibodies | Day 0 | 21.2 titer |
| Placebo | Geometric Mean Titer of Microneutralizing (MN) Antibodies | Day 21 | 595.1 titer |
| Placebo | Geometric Mean Titer of Microneutralizing (MN) Antibodies | Day 42 | 725.7 titer |
| Influenza Vaccine | Geometric Mean Titer of Microneutralizing (MN) Antibodies | Day 21 | 18.9 titer |
| Influenza Vaccine | Geometric Mean Titer of Microneutralizing (MN) Antibodies | Day 0 | 17.7 titer |
| Influenza Vaccine | Geometric Mean Titer of Microneutralizing (MN) Antibodies | Day 42 | 18.9 titer |
Secondary
Number and Percentage of All Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI)
Day 21 and 42 blood samples from study subjects (n=48) were tested. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The hemagglutination titer was reported as the reciprocal of the highest dilution that caused hemagglutination and was expressed in HA units (HAU)/50μL, calculated as the average of results of duplicate wells.
Time frame: Day 21 and Day 42
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Placebo | Number and Percentage of All Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) | Day 21 | 4-fold rise or higher | 20 Participants |
| Placebo | Number and Percentage of All Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) | Day 21 | Less than 4-fold rise | 3 Participants |
| Placebo | Number and Percentage of All Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) | Day 42 | 4-fold rise or higher | 21 Participants |
| Placebo | Number and Percentage of All Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) | Day 42 | Less than 4-fold rise | 2 Participants |
| Placebo | Number and Percentage of All Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) | Day 21 or 42 | 4-fold rise or higher | 22 Participants |
| Placebo | Number and Percentage of All Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) | Day 21 or 42 | Less than 4-fold rise | 1 Participants |
| Influenza Vaccine | Number and Percentage of All Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) | Day 21 or 42 | 4-fold rise or higher | 0 Participants |
| Influenza Vaccine | Number and Percentage of All Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) | Day 21 | 4-fold rise or higher | 0 Participants |
| Influenza Vaccine | Number and Percentage of All Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) | Day 42 | Less than 4-fold rise | 25 Participants |
| Influenza Vaccine | Number and Percentage of All Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) | Day 21 | Less than 4-fold rise | 25 Participants |
| Influenza Vaccine | Number and Percentage of All Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) | Day 21 or 42 | Less than 4-fold rise | 25 Participants |
| Influenza Vaccine | Number and Percentage of All Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) | Day 42 | 4-fold rise or higher | 0 Participants |
Secondary
Number and Percentage of All Subjects Achieving a Four-fold Rise in Microneutralization (MN) Antibodies
Day 21 and 42 specimens were tested in the microneutralization (MN) assay. The microneutralization assay determines the titer of neutralizing antibodies against influenza A/H1N1. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The 50% neutralizing antibody titer is the reciprocal of the corresponding serum dilution. The geometric mean titers (GMT) and corresponding confidence intervals were based on a log 10 scale.
Time frame: Day 21 and Day 42
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Placebo | Number and Percentage of All Subjects Achieving a Four-fold Rise in Microneutralization (MN) Antibodies | Day 21 | Less than 4-fold rise | 4 Participants |
| Placebo | Number and Percentage of All Subjects Achieving a Four-fold Rise in Microneutralization (MN) Antibodies | Day 21 | 4-fold rise or higher | 19 Participants |
| Placebo | Number and Percentage of All Subjects Achieving a Four-fold Rise in Microneutralization (MN) Antibodies | Day 42 | 4-fold rise or higher | 22 Participants |
| Placebo | Number and Percentage of All Subjects Achieving a Four-fold Rise in Microneutralization (MN) Antibodies | Day 42 | Less than 4-fold rise | 1 Participants |
| Placebo | Number and Percentage of All Subjects Achieving a Four-fold Rise in Microneutralization (MN) Antibodies | Day 21 or 42 | 4-fold rise or higher | 22 Participants |
| Placebo | Number and Percentage of All Subjects Achieving a Four-fold Rise in Microneutralization (MN) Antibodies | Day 21 or 42 | Less than 4-fold rise | 1 Participants |
| Influenza Vaccine | Number and Percentage of All Subjects Achieving a Four-fold Rise in Microneutralization (MN) Antibodies | Day 21 or 42 | 4-fold rise or higher | 0 Participants |
| Influenza Vaccine | Number and Percentage of All Subjects Achieving a Four-fold Rise in Microneutralization (MN) Antibodies | Day 42 | Less than 4-fold rise | 25 Participants |
| Influenza Vaccine | Number and Percentage of All Subjects Achieving a Four-fold Rise in Microneutralization (MN) Antibodies | Day 21 | 4-fold rise or higher | 0 Participants |
| Influenza Vaccine | Number and Percentage of All Subjects Achieving a Four-fold Rise in Microneutralization (MN) Antibodies | Day 21 | Less than 4-fold rise | 25 Participants |
| Influenza Vaccine | Number and Percentage of All Subjects Achieving a Four-fold Rise in Microneutralization (MN) Antibodies | Day 21 or 42 | Less than 4-fold rise | 25 Participants |
| Influenza Vaccine | Number and Percentage of All Subjects Achieving a Four-fold Rise in Microneutralization (MN) Antibodies | Day 42 | 4-fold rise or higher | 0 Participants |
Secondary
Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Greater Than 40
Day 21 and 42 blood samples from study subjects (n=48) were tested. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The hemagglutination titer was reported as the reciprocal of the highest dilution that caused hemagglutination and was expressed in HA units (HAU)/50μL, calculated as the average of results of duplicate wells.
Time frame: Day 21 and Day 42
Population: Subjects with baseline titer \>=40
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Placebo | Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Greater Than 40 | Day 21 | Less than 4-fold rise | 1 Participants |
| Placebo | Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Greater Than 40 | Day 42 | Less than 4-fold rise | 2 Participants |
| Placebo | Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Greater Than 40 | Day 42 | 4-fold rise or higher | 4 Participants |
| Placebo | Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Greater Than 40 | Day 21 | 4-fold rise or higher | 5 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Greater Than 40 | Day 42 | 4-fold rise or higher | 0 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Greater Than 40 | Day 42 | Less than 4-fold rise | 7 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Greater Than 40 | Day 21 | Less than 4-fold rise | 7 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Greater Than 40 | Day 21 | 4-fold rise or higher | 0 Participants |
Secondary
Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Less Than 40
Day 21 and Day 42 blood samples from study subjects (n=48) were tested. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The hemagglutination titer was reported as the reciprocal of the highest dilution that caused hemagglutination and was expressed in HA units (HAU)/50μL, calculated as the average of results of duplicate wells.
Time frame: Day 21 and Day 42
Population: Subjects with baseline titer \<40
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Placebo | Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Less Than 40 | Day 21 | 4-fold rise or higher | 15 Participants |
| Placebo | Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Less Than 40 | Day 21 | Less than 4-fold rise | 2 Participants |
| Placebo | Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Less Than 40 | Day 42 | 4-fold rise or higher | 17 Participants |
| Placebo | Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Less Than 40 | Day 42 | Less than 4-fold rise | 0 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Less Than 40 | Day 42 | Less than 4-fold rise | 18 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Less Than 40 | Day 21 | 4-fold rise or higher | 0 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Less Than 40 | Day 42 | 4-fold rise or higher | 0 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Achieving a Four-fold Rise in Hemagglutination-inhibition Antibodies (HAI) Among Subjects With Baseline Titer Less Than 40 | Day 21 | Less than 4-fold rise | 18 Participants |
Secondary
Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Greater Than 40
Day 21 and 42 specimens were tested in the microneutralization (MN) assay. The microneutralization assay determines the titer of neutralizing antibodies against influenza A/H1N1. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The 50% neutralizing antibody titer is the reciprocal of the corresponding serum dilution. The geometric mean titers (GMT) and corresponding confidence intervals were based on a log 10 scale.
Time frame: Day 21 and Day 42
Population: Subjects with baseline titer \>=40
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Placebo | Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Greater Than 40 | Day 21 | 4-fold rise or higher | 9 Participants |
| Placebo | Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Greater Than 40 | Day 21 | Less than 4-fold rise | 3 Participants |
| Placebo | Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Greater Than 40 | Day 42 | Less than 4-fold rise | 1 Participants |
| Placebo | Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Greater Than 40 | Day 42 | 4-fold rise or higher | 11 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Greater Than 40 | Day 42 | Less than 4-fold rise | 10 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Greater Than 40 | Day 21 | 4-fold rise or higher | 0 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Greater Than 40 | Day 21 | Less than 4-fold rise | 10 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Greater Than 40 | Day 42 | 4-fold rise or higher | 0 Participants |
Secondary
Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Less Than 40
Day 21 and 42 blood samples from study subjects (n=48) were tested. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The hemagglutination titer was reported as the reciprocal of the highest dilution that caused hemagglutination and was expressed in HA units (HAU)/50μL, calculated as the average of results of duplicate wells.
Time frame: Day 21 and Day 42
Population: Subjects with baseline titer \<40
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Placebo | Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Less Than 40 | Day 21 | 4-fold rise or higher | 10 Participants |
| Placebo | Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Less Than 40 | Day 21 | Less than 4-fold rise | 1 Participants |
| Placebo | Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Less Than 40 | Day 42 | 4-fold rise or higher | 11 Participants |
| Placebo | Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Less Than 40 | Day 42 | Less than 4-fold rise | 0 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Less Than 40 | Day 42 | Less than 4-fold rise | 15 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Less Than 40 | Day 21 | 4-fold rise or higher | 0 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Less Than 40 | Day 42 | 4-fold rise or higher | 0 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Achieving a Four-fold Rise in Microneutralizing (MN) Antibodies Among Subjects With Baseline Titer Less Than 40 | Day 21 | Less than 4-fold rise | 15 Participants |
Secondary
Number and Percentage of Subjects Developing a Seroprotective Hemagglutination-inhibition (HAI) Antibody Titer
Seroprotection defined as an HAI titer ≥1:40. Day 21 and 42 blood samples from study subjects (n=48) were tested. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The hemagglutination titer was reported as the reciprocal of the highest dilution that caused hemagglutination and was expressed in HA units (HAU)/50μL, calculated as the average of results of duplicate wells.
Time frame: Day 21 and Day 42
Population: Includes subjects who had a baseline titer of \<1:40.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Placebo | Number and Percentage of Subjects Developing a Seroprotective Hemagglutination-inhibition (HAI) Antibody Titer | Day 21 | Response | 15 Participants |
| Placebo | Number and Percentage of Subjects Developing a Seroprotective Hemagglutination-inhibition (HAI) Antibody Titer | Day 21 | No response | 2 Participants |
| Placebo | Number and Percentage of Subjects Developing a Seroprotective Hemagglutination-inhibition (HAI) Antibody Titer | Day 42 | Response | 17 Participants |
| Placebo | Number and Percentage of Subjects Developing a Seroprotective Hemagglutination-inhibition (HAI) Antibody Titer | Day 42 | No response | 0 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Developing a Seroprotective Hemagglutination-inhibition (HAI) Antibody Titer | Day 42 | No response | 17 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Developing a Seroprotective Hemagglutination-inhibition (HAI) Antibody Titer | Day 21 | Response | 0 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Developing a Seroprotective Hemagglutination-inhibition (HAI) Antibody Titer | Day 42 | Response | 1 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Developing a Seroprotective Hemagglutination-inhibition (HAI) Antibody Titer | Day 21 | No response | 18 Participants |
Secondary
Number and Percentage of Subjects Developing a Seroprotective Microneutralizing (MN) Antibody Titer
Seroprotection defined as an antibody titer of 1:40 or greater. Day 21 and 42 specimens were tested in the microneutralization (MN) assay. The microneutralization assay determines the titer of neutralizing antibodies against influenza A/H1N1. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The 50% neutralizing antibody titer is the reciprocal of the corresponding serum dilution. The geometric mean titers (GMT) and corresponding confidence intervals were based on a log 10 scale.
Time frame: Day 21 and Day 42
Population: Includes subjects who had a baseline titer of \<1:40.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Placebo | Number and Percentage of Subjects Developing a Seroprotective Microneutralizing (MN) Antibody Titer | Day 21 | Seroprotection | 9 Participants |
| Placebo | Number and Percentage of Subjects Developing a Seroprotective Microneutralizing (MN) Antibody Titer | Day 21 | No seroprotection | 2 Participants |
| Placebo | Number and Percentage of Subjects Developing a Seroprotective Microneutralizing (MN) Antibody Titer | Day 42 | No seroprotection | 0 Participants |
| Placebo | Number and Percentage of Subjects Developing a Seroprotective Microneutralizing (MN) Antibody Titer | Day 42 | Seroprotection | 11 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Developing a Seroprotective Microneutralizing (MN) Antibody Titer | Day 42 | No seroprotection | 15 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Developing a Seroprotective Microneutralizing (MN) Antibody Titer | Day 21 | Seroprotection | 0 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Developing a Seroprotective Microneutralizing (MN) Antibody Titer | Day 21 | No seroprotection | 15 Participants |
| Influenza Vaccine | Number and Percentage of Subjects Developing a Seroprotective Microneutralizing (MN) Antibody Titer | Day 42 | Seroprotection | 0 Participants |
Secondary
Ratio of Geometric Mean Titer of Hemagglutination-inhibition Antibodies (HAI)
Day 0, 21 and 42 blood samples from study subjects (n=48) were tested. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The hemagglutination titer was reported as the reciprocal of the highest dilution that caused hemagglutination and was expressed in HA units (HAU)/50μL, calculated as the average of results of duplicate wells.
Time frame: Day 0, Day 21 and Day 42
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Placebo | Ratio of Geometric Mean Titer of Hemagglutination-inhibition Antibodies (HAI) | Day 21/Day 0 | 22.69 ratio |
| Placebo | Ratio of Geometric Mean Titer of Hemagglutination-inhibition Antibodies (HAI) | Day 42/Day 0 | 20.99 ratio |
| Placebo | Ratio of Geometric Mean Titer of Hemagglutination-inhibition Antibodies (HAI) | Day 42/Day 21 | 0.93 ratio |
| Influenza Vaccine | Ratio of Geometric Mean Titer of Hemagglutination-inhibition Antibodies (HAI) | Day 21/Day 0 | 0.97 ratio |
| Influenza Vaccine | Ratio of Geometric Mean Titer of Hemagglutination-inhibition Antibodies (HAI) | Day 42/Day 0 | 1.03 ratio |
| Influenza Vaccine | Ratio of Geometric Mean Titer of Hemagglutination-inhibition Antibodies (HAI) | Day 42/Day 21 | 1.06 ratio |
Secondary
Ratio of Geometric Mean Titer of Microneutralization (MN) Antibodies
Day 0, 21 and 42 specimens were tested in the microneutralization (MN) assay. The microneutralization assay determines the titer of neutralizing antibodies against influenza A/H1N1. The assay is performed in duplicate wells of 2-fold serial dilutions of serum. The 50% neutralizing antibody titer is the reciprocal of the corresponding serum dilution. The geometric mean titers (GMT) and corresponding confidence intervals were based on a log 10 scale.
Time frame: Day 0, Day 21 and Day 42
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Placebo | Ratio of Geometric Mean Titer of Microneutralization (MN) Antibodies | Day 21/Day 0 | 28.01 ratio |
| Placebo | Ratio of Geometric Mean Titer of Microneutralization (MN) Antibodies | Day 42/Day 0 | 34.16 ratio |
| Placebo | Ratio of Geometric Mean Titer of Microneutralization (MN) Antibodies | Day 42/Day 21 | 1.22 ratio |
| Influenza Vaccine | Ratio of Geometric Mean Titer of Microneutralization (MN) Antibodies | Day 21/Day 0 | 1.07 ratio |
| Influenza Vaccine | Ratio of Geometric Mean Titer of Microneutralization (MN) Antibodies | Day 42/Day 0 | 1.07 ratio |
| Influenza Vaccine | Ratio of Geometric Mean Titer of Microneutralization (MN) Antibodies | Day 42/Day 21 | 1.00 ratio |